DeNovaMed
DeNovaMed is a pioneering pharmaceutical company dedicated to developing innovative antibiotics to combat bacterial infections and drug resistance. Their focus includes addressing serious health issues such as diabetic foot ulcers, bacterial infections, and antibiotic-resistant strains. The company leverages advanced drug design, computer-aided drug discovery, and a strong team of experts to create novel therapies with broad therapeutic potential. DeNovaMed aims to provide effective solutions to global health challenges posed by resistant bacteria and to lead in antibiotic innovation.
Industries
Nr. of Employees
small (1-50)
DeNovaMed
Sir Charles Tupper Medical Building, Dalhousie University Suite 1A-1; 5850 College Street Halifax, Nova Scotia B3H 4H7
Patents
Diphenyl substituted thiophene-2-amide derivatives and pharmaceutical compositions thereof useful as antimicrobial
US-11306067-B2
View Details
Diphenyl substituted thiophene-2-amide derivatives and pharmaceutical compositions thereof useful as antimicrobial
US-11306067-B2
View DetailsExpertise Areas
- Antibacterial drug discovery
- Computer-aided drug design (computational medicinal chemistry)
- Novel mechanism-of-action development (lipid metabolism / ACP synthase targeting)
- Preclinical development and lead optimization
Key Technologies
- Computer-aided drug design (de novo molecular modeling)
- ACP synthase (AcpS) inhibition
- De novo small-molecule library synthesis
- Minimum inhibitory concentration (MIC) assays
News & Updates
Research on the design and optimization of hundreds of novel compounds against ACP synthase, culminating in preclinical candidate DNM0547, published in Nature Communications.
Development of a new family of antibiotics to treat multidrug-resistant bacteria, addressing a major global health threat, with validation from peer-reviewed publication.
Issued Patents
DeNovaMed has over 6 issued patents related to their antibiotic compounds and technology.
Research Milestones
Development of novel antibiotics DNM0547 and DNM0904, with successful preclinical testing and publication in scientific journals.
Research on the design and optimization of hundreds of novel compounds against ACP synthase, culminating in preclinical candidate DNM0547, published in Nature Communications.
Development of a new family of antibiotics to treat multidrug-resistant bacteria, addressing a major global health threat, with validation from peer-reviewed publication.
Issued Patents
DeNovaMed has over 6 issued patents related to their antibiotic compounds and technology.
Research Milestones
Development of novel antibiotics DNM0547 and DNM0904, with successful preclinical testing and publication in scientific journals.